Titan Receives SBIR Grant to Investigate Long Term Treatment for Parkinson’s Disease

Titan Receives SBIR Grant to Investigate Long Term Treatment for Parkinson’s Disease
SOUTH SAN FRANCISCO, Calif., July 26 /PRNewswire-FirstCall/ — Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today announced that the National Institutes of Health (NIH) has awarded the company a grant under the Small Business Innovation Research (SBIR) program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson’s disease. The first year …
Read more on redOrbit

NIH issues SBIR grant to Titan pharmaceutical for Parkinson’s disease treatment
Titan Pharmaceuticals, Inc.today announced that the National Institutes of Health (NIH) has awarded the company a grant under the Small Business Innovation Research (SBIR) program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson’s disease. The first year award in the amount of 0,000 will be available to Titan starting August 1, 2010, and an …
Read more on News-Medical-Net

Titan Receives SBIR Grant to Investigate Long Term Treatment for Parkinson’s Disease
Titan Pharmaceuticals, Inc. today announced that the National Institutes of Health has awarded the company a grant under the Small Business Innovation Research program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson’s disease.
Read more on PR Newswire via Yahoo! Finance